United Therapeutics Announces $477.6 Million Share Repurchase Amid Pipeline Funding Concerns
On September 8, United Therapeutics (NASDAQ:UTHR) committed the remaining $477.6 million under its $2 billion share repurchase authorization to an accelerated buyback with Citibank, N.A., bringing total capital returned close to $4 billion over two and a half years. The company has already executed $1.5 billion in accelerated purchases and $22.4 million through open-market transactions this year. United Therapeutics reported strong cash reserves of $3.803 billion as of June 30, with first-half operating cash flow reaching $776.9 million. However, the company has faced pressure from capital expenditures for facility construction and recent acquisitions like Thymmune Therapeutics in July. The firm is also awaiting FDA decisions on two key drug candidates: ralinepag (target action date June 24, 2027) and Nebulized Tyvaso (expected decision by late April 2027). Despite robust cash generation, concerns remain about whether the company can sustain its aggressive buyback program while funding ongoing research, facility expansions, and potential future payments tied to acquisitions. Second-quarter revenue declined slightly due in part to competitive pressures affecting key products like Tyvaso.
Tickers: $UTHR
Topics: buybacks capital_return cash_flow